Rain could lead to more mosquitoes in Minnesota, experts say
Could the number of mosquitoes still increase in Minnesota this summer?
Could the number of mosquitoes still increase in Minnesota this summer?
As Minnesotans prepare for backyard barbeques, an uninvited guest is making a strong comeback: mosquitoes.
Experts say cooler weather and low river levels could be responsible for our slow start to the mosquito season.
"Right now, mosquitos are well below average this time of year. But they're starting to creep back up," said Alex Carlson, with the Metropolitan Mosquito Control District.
Carlson says this year was the first time in three years we did not see a significant emergence of spring mosquitoes in May and early June. Rainfall expected this week could lead to significant increase. Specifically, a common summer nuisance, "cattail mosquitoes."
"They are very aggressive. They love to feed on us, but fortunately they typically don't carry disease just annoying and cause big red welts," Carlson said.
In response, aerial and ground treatments will continue as MMCD jump back into their busy season.
"We're going to be very busy next couple of days trying to get helicopters and getting staff out to do our treatments now, so we can knock down the population before the 4th of July," Carlson said.
Avoiding bites isn't just what officials do, it starts before you leave your house.
Mosquito control experts say there are some easy steps you can follow:
Make sure not to skip bug spray. Avoid dusk and dawn, when mosquitoes are most active. Skip sweet scents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Butterfly Network to Report Second Quarter 2025 Financial Results on August 1, 2025
BURLINGTON, Mass. & NEW YORK, July 18, 2025--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report second quarter 2025 financial results on August 1, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on August 1 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time: United States (Toll-Free): +1 833-470-1428United States (Local): +1 404-975-4839Global Dial-In Numbers: Access Code: 685760 After the live webcast, the call will be archived on Butterfly's Investor Relations page. In addition, a telephone replay of the call will be available until August 15, 2025, by dialing: United States (Toll-Free): +1 866 813 9403United States (Local): +1 929 458 6194Access Code: 128350 About Butterfly Network Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: View source version on Contacts Butterfly Investors: Heather GetzChief Financial and Operations Officer, Butterflyinvestors@ Sign in to access your portfolio
Fast Company
20 minutes ago
- Fast Company
What is chronic venous insufficiency? Trump diagnosis puts the condition in the spotlight
Swollen legs led to President Donald Trump being diagnosed with what's called chronic venous insufficiency. It's a fairly common condition among older adults but requires a thorough checkup to rule out more serious causes of swelling in the legs. Here are some things to know. What is chronic venous insufficiency? Chronic venous insufficiency, or CVI, happens when veins in the legs can't properly carry blood back to the heart. That can lead to blood pooling in the lower legs. In addition to swelling, usually around the feet and ankles, symptoms can include legs that are achy, heavy feeling or tingly, and varicose veins. Severe cases could trigger leg sores known as ulcers. What causes chronic venous insufficiency? Overcoming gravity to pump blood from the feet all the way up to the heart is a challenge, especially when someone is standing or sitting for long periods. So legs veins are lined with one-way valves that keep blood from sliding backward on that journey. Anything that damages those valves can lead to chronic venous insufficiency. Risk factors can include blood clots, vein inflammation known as phlebitis or being overweight. How is chronic venous insufficiency diagnosed and treated? Doctors must rule out serious causes of leg swelling, such as heart problems, kidney disease or blood clots. Ultrasound exams of the leg veins can help confirm chronic venous insufficiency. According to the Cleveland Clinic, treatment can include wearing compression stockings, elevating the legs and achieving a healthy weight. Also exercise, especially walking, is recommended — because strong leg muscles can squeeze veins in a way that helps them pump blood. Medications and medical procedures are available for more advanced cases. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Medscape
20 minutes ago
- Medscape
Adherence to Male Hypogonadism Treatment Guidelines Is Low
SAN FRANCISCO — Adherence to diagnostic and treatment guidelines for male hypogonadism is quite low, with significant differences among medical specialists, a new study found. Off-label use of testosterone replacement therapy (TRT) has risen in recent years, corresponding with the advent of direct-to-consumer (DTC) advertising for TRT and the emergence of 'low T' clinics, Petra Pederson, MD, PhD, chief resident in internal medicine at Scripps Clinic/Green Hospital, San Diego, said at the ENDO 2025: The Endocrine Society Annual Meeting. 'This led to our hypothesis that [DTC] advertising in the presence of online clinics creates patient expectations that make it challenging for clinicians to practice evidence- and guideline-based care,' she said. Pederson and colleagues conducted a two-part study of adherence to TRT prescribing guidelines at their institution. The first part involved a retrospective chart review of 269 men who were prescribed TRT from January 1, 2019, through June 30, 2023, examining adherence to the 2018 Endocrine Society clinical practice guideline (CPG). Of the 269 TRT prescriptions, 67.3% were from primary care providers (54% internal medicine and 13% family medicine) and 32.7% from specialists (25% urology and 8% endocrinology). The majority of patients (72.1%) stayed on treatment for at least 1 year, with an average treatment duration of 25 months. Criteria for adherence was defined as: Confirmation of the diagnosis of hypogonadism with two separate low (< 264 ng/dL) early morning total testosterone levels. Determination of the etiology of hypogonadism by measuring luteinizing hormone (LH) and follicle-stimulating hormone (FSH) with appropriate laboratory or imaging follow-up based on the results. On-treatment therapeutic monitoring with total testosterone levels drawn at 3-6 months and 12 months. On-treatment safety monitoring, with hematocrit at baseline and at 3-6 months, with dose reduction if necessary and discontinuation if > 54%. Overall, the proportion of clinicians, primary care, and specialists combined who followed all four criteria was just 5.9%. The difference between primary care (3.3%) and specialists (11.4%) was statistically significant ( P = .009). By individual criteria, 17.8% overall had no low testosterone level prior to treatment, 21% among the primary care group vs 10.2% for the specialists. This difference was also significant ( P = .023). Follow-up total testosterone measurement at 3-6 months was performed for only 50% overall, 44.1% by primary care, and 62.5% by the specialists. Hematocrit testing at 3-6 months was measured at 54% overall, 48.0% by the primary care, and 65.3% by specialists. Both specialty differences were again significant ( P = .01 and P = .06, respectively). Between the two specialties, endocrinologists were more likely than urologists to follow all four criteria, 23.8% vs 7.5%, respectively ( P = .054), and were much more likely to have LH and FSH drawn (85.7% vs 16.4% for LH; P < .001). 'We postulate that these striking differences between endocrinology and urology could be related to the fact that urologists were seeing more patients who present with sexual dysfunction compared to endocrinologists, and perhaps they have more pressure to prescribe,' Pederson said. Barriers: DTC Advertising, Misinformation, Test Inaccuracy The second part of the study involved a survey to which 51 Scripps providers responded. Of those, 74% were primary care (41% internal medicine and 33% family medicine), 18% endocrinologists, and 8% urologists. All 51 reported having seen one or more patients in the last 6 months who requested TRT. The specialists were significantly more likely to report being comfortable with the guidelines than were the primary care providers and to prescribe TRT more often. A total of 74.5% overall felt that DTC advertising and testosterone 'clinics' were significant public health issues. A similar majority (76.5%) felt there was a need for more educational tools. Barriers to providing guideline-based care identified by the providers included misinformation through advertising or social media, for-profit 'low T' clinics that contradict evidence-based guidelines, patient dissatisfaction when guidelines don't align with their expectations, vague and subjective symptoms, and test inaccuracy and variability. 'We're planning to address this at our institution with a quality improvement initiative,' Pederson said. She acknowledged that the American Urological Association guidelines use a low testosterone cutoff of < 300 ng/dL, 'so we might underestimate guideline adherence with our criteria.' And she noted that a small number of primary care providers accounted for a disproportionate number of the prescriptions in their sample, which could limit generalizability. In response to a question from the audience about why the guideline adherence was so low even among specialists, Pederson responded, 'I think that they're experiencing some of the same challenges that PCPs are experiencing, which is the pressure from their patients, and also maybe issues related to tests and accuracy. And I just think the difficulty of getting patients to do all these follow-up tests when they're looking for a simple fix.' Improvements Are Underway, Patient Education Is Key Asked to comment, the Endocrine Society's CPG lead author Shalender Bhasin, MB, professor of medicine at Harvard Medical School and director of the Research Program in Men's Health: Aging and Metabolism at Brigham and Women's Hospital, Boston, told Medscape Medical News that these findings align with those of a study his group conducted a decade ago in the Veterans Administration (VA), but that the VA has since implemented system-wide improvements. 'I think it's gotten much better. In the VA, it was very low, and it has gotten substantially better because at the VA now there's one policy. Also, the assays have gotten better.' Bhasin also pointed out that the prescribing of testosterone has fluctuated over time, dropping in 2013 after an FDA advisory about cardiovascular risk but then rising again around 2017 following the TRAVERSE trial results showing cardiovascular safety. The subsequent rise has been slower, but, Bhasin noted, 'testosterone sales are growing, and at the same time, many men with testosterone deficiency remain undiagnosed, so it's both overuse and underuse.' Also asked to comment, session moderator Ismat Shafiq, MD, of the University of Rochester, Rochester, New York, told Medscape Medical News that patients will commonly have low total testosterone due to overweight or obesity and/or sleep apnea but will have normal free testosterone. 'If that's the case, we can properly educate our patients and work on managing their weight and sleep problems. That can reverse the hypogonadism and make them feel better, rather than giving them testosterone.' And if they have both low total and free testosterone, the cause could be something reversible, such as a prolactinoma or pituitary macroadenoma. 'If we check the prolactin level and we treat them, the hypogonadism will resolve. Primary hypothyroidism, too, if treated, can resolve the hypogonadism,' Shafiq said. 'Diagnosing the patient appropriately can identify causes that can be treatable and that can improve their quality of life and improve their testosterone level too, rather than jumping into giving them testosterone.' She also noted that many patients mistakenly believe that more testosterone is better. 'We need to educate them. In my experience, most of the patients listen and understand because nobody wants to take extra medicine all the time, unless it's really needed for them to improve their quality of life.' Pederson and Shafiq reported having no disclosures. Bhasin reported receiving research grant support from AbbVie and Metro International Biotech for investigator-initiated research, with the grants managed by Brigham and Women's Hospital. He has served as a consultant to Besins and Versanis and has an equity interest in XYone Therapeutics.
